In an effort to promote its latest ventilation and respiratory product line, CareFusion Corp. (CFN) unveiled several new products at the American Association for Respiratory Care (AARC) Congress. Some of the new devices that were on display included the Ventilator Associated Event (VAE) application, AirLife Misty Fast disposable small-volume nebulizer (SVN), Vmax Vyntus SPIRO and the LTV Series ventilators.
The company’s shares had slipped slightly after reporting flattish fiscal 2014 first-quarter results on Nov 8. However, immediately thereafter CFN’s shares picked up pace and is currently trading at $38.73 as of Nov 19. However, these product launches (announced on Nov 15) failed to create any significant impact on the share price.
The VAE technology on the CareFusion Knowledge Portal is capable of providing vital information to doctors regarding near-real time patient conditions. It is also equipped to identify whether the patient is at a risk of developing a ventilator-associated condition. This significantly helps to improve patient outcome along with clinical efficiency.
The new AirLife Misty Fast SVN and the AirLife manual self-inflating resuscitation devices II were also displayed at the AARC Congress. According to a study, the AirLife Misty Fast SVN can deliver efficacious drugs (drugs within respirable range of one to five microns) much faster than four other SVNs tested therein.
CareFusion’s latest Vmax Vyntus SPIRO is used for pulmonary function testing. Additionally, the company also intends to conduct a workshop on CFN’s LTV Series ventilators at the event. The light-weight and uncomplicated design of the LTV Ventilator allows for easy mobility in emergency situations that require critical care invasive and non-invasive ventilation.
CareFusion is a global corporation serving the health care industry with products and services that help hospitals to measurably improve standards of care. We believe that the company will be able to garner significant revenues from its latest offerings in the ventilation and respiratory portfolio.
Currently, CareFusion has a Zacks Rank #3 (Hold). However, stocks that are performing relatively better in the medical products industry include Hill-Rom Holdings, Inc. (HRC), NuVasive, Inc. (NUVA) and Medtronic (MDT). HRC and NUVA carry a Zacks Rank #1 (Strong Buy), while MDT sports a Zacks Rank #2 (Buy).
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment